Piramed's exit scheme

Phosphoinositide 3-kinase is a hot target area where multiple companies are working. The one Roche picked to buy, Piramed Ltd., includes scientific founders who were among the first in the field.

Roche is paying $160 million in cash for Piramed, plus a potential milestone of $15 million. ...